Zolpisys 133mg/58mg Tablet CR
Marketer
Human Biolife India Pvt Ltd
Salt Composition
Sodium Valproate (133mg) + Valproic Acid (58mg)
Overview Zolpisys 133mg/58mg Tablet CR
Epileptrol CR 133mg/58mg tablets combine two active agents to manage epilepsy, a neurological condition marked by recurring seizures. This medication regulates aberrant brain activity, promoting nerve relaxation and seizure prevention. Epileptrol CR should be administered with food; dosage, determined by your physician, may be gradually increased until your condition stabilizes. Therapeutic effects may take weeks to manifest; consistent use is crucial. Discontinuation, except under medical supervision, risks seizure recurrence and potential bipolar disorder exacerbation. Common side effects include nausea and tremors; others, such as vomiting, headache, hepatic impairment, and upper abdominal discomfort, are possible. Persistent or bothersome side effects warrant medical attention; management strategies often exist. Prior to initiating treatment, disclose any kidney or liver disease, meningitis, depression, or suicidal ideation. Inform your doctor of all concurrent medications, including contraceptives, due to potential interactions. While use during pregnancy or breastfeeding is possible if deemed essential, dosage adjustments may be necessary. Avoid driving or cycling if drowsiness or dizziness occurs. Regular blood tests monitor treatment response. Alcohol should be avoided as it may intensify side effects. Weight gain is a potential consequence; maintain a healthy diet, limit high-calorie snacks, and engage in regular exercise. Report any unusual mood or behavioral changes, new or worsening depression, or suicidal thoughts or actions to your doctor immediately.
Primary Ingredients of Zolpisys 133mg/58mg Tablet CR
No text provided. Please provide the text you wish me to rephrase.
Uses of Zolpisys 133mg/58mg Tablet CR
Seizure disorder
Major Benefits of Zolpisys 133mg/58mg Tablet CR:
Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment length. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. The Zolpisys 133mg/58mg Controlled-Release tablet should be administered with a meal.
Common Side effects of Zolpisys 133mg/58mg Tablet CR:
- Nausea
- Tremors
How to use Zolpisys 133mg/58mg Tablet CR:
Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment length. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. The Zolpisys 133mg/58mg Controlled-Release tablet should be taken with a meal.
How Zolpisys 133mg/58mg Tablet CR works:
Each Zolpisys 133mg/58mg Controlled-Release tablet contains a dual anticonvulsant formulation comprising sodium valproate and valproic acid.
SAFETY ADVICE
AlcoholUNSAFE
Combining Zolpisys 133mg/58mg CR tablets with alcohol is unsafe.
PregnancyCONSULT YOUR DOCTOR
Use of Zolpisys 133mg/58mg Controlled-Release tablets during pregnancy poses a confirmed risk to the fetus. Prescribing may occur exceptionally in critical circumstances where potential benefits outweigh the known hazards. Always seek medical advice.
Breast feedingSAFE IF PRESCRIBED
Extended-release Zolpisys 133mg/58mg tablets are considered safe for breastfeeding mothers. Research in humans indicates minimal drug transfer to breast milk, posing no appreciable risk to the infant.
DrivingUNSAFE
Taking Zolpisys 133mg/58mg CR tablets may cause drowsiness, blurred vision, and dizziness. Refrain from driving if you experience these effects.
KidneySAFE IF PRESCRIBED
Use of Zolpisys 133mg/58mg Tablet CR in individuals with kidney impairment appears to present minimal risk. Current evidence indicates dose modification may be unnecessary, but this requires individual assessment. Physician consultation is advised, especially if you have pre-existing kidney conditions.
LiverCAUTION
Patients with liver impairment should exercise caution when using Zolpisys 133mg/58mg CR tablets. A modified dosage of Zolpisys 133mg/58mg CR tablets may be necessary; physician consultation is advised. Zolpisys 133mg/58mg CR tablets are contraindicated in individuals with severe or active liver disease.
What if you forget to take Zolpisys 133mg/58mg Tablet CR :
Should you forget to take a Zolpisys 133mg/58mg CR tablet, administer it at your earliest convenience. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Zolpisys 133mg/58mg Tablet CR
| Label | Value |
|---|---|
| Developing Habits | No. |
| Treatment Category | Central Nervous System (CNS) Neurology |
3,018 People bought this recently